Question-and-Answer Session
Operator
(Operator Instructions). Your first question comes from the line of Eun Yang.
Eun Yang - Jefferies & Company
Thanks very much. Jonathan, I wasn't clear in your Cheetah program whether you are reformulating insulin using generic insulin or fast-acting insulin?
Jonathan Lim
Yeah Eun, we are taking both, so we are taking both the fast-acting insulin analogs and we are also taking regular insulin, and checking to co-formulate them with our enzyme.
Eun Yang - Jefferies & Company
So when you would see use of fast-acting insulin's and as a Humalog on Novolog but those are patent protected. So, what would be your development strategy for those compounds?
Jonathan Lim
Yeah, it gives us a very flexible strategy where we can seek to partner the analogs, as well as develop the regular products on our own. And so we are open to all strategic scenarios at this point.
Eun Yang - Jefferies & Company
Okay. And then second question, it is a little bit more general. Just looking at the drug industry in general, the business of reformulating existing drugs is somewhat under stress. So what I want to ask you is that, obviously, you guys are in a business over co-formulating existing products and try to make it better.
So I am wondering in the clinical development, and as well as for our potential regulatory approval, whether you may need to provide some clinical benefits in terms of efficacy or when you reformulate existing products beyond, just providing convenience, as well as the compliance benefit?
Jonathan Lim
That's right. And Eun that's why we are excited about Cheetah because we hope that the data will show advantages relative to the existing agents in the market, not just from a convenience and compliance perspective but from a meaningful clinical benefit perspective. And by shifting the PK and PD in this particular class of molecules, we believe that a meaningful clinical benefit can be demonstrated by achieving a more physiologic insulin profile which means better glycemic control in terms of fewer hypo and hyperglycemic excursions.
And then also, the home run would be if there can be a weight control or less weight gain in the type 2 Diabetic population which is a much more significant patient base in terms of numbers. But this is one opportunity where PK and PD actually translates into a meaningful clinical benefit from an efficacy perspective.
- To read the full transcript on Seeking Alpha, click here »
